11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 13.09.2026 Expectation: 150 pips
Selling ETHUSD down to $1,750
Today at 10:45 AM 24
Gold buy
Period: 30.09.2026 Expectation: 46000 pips
Going long on gold amid slowdown in US inflation
Today at 10:33 AM 31
Period: 31.10.2026 Expectation: 1100 pips
Invest in EURUSD up to 1.16400
Today at 10:33 AM 19
Period: 13.09.2026 Expectation: 250 pips
Buying S&P 500 with 8,000 target
Today at 08:35 AM 47
Period: 26.08.2026 Expectation: 1850 pips
EURUSD sell-off targets 1.13500
Yesterday at 11:12 AM 39
Period: 31.08.2026 Expectation: 800 pips
Selling EURUSD on high US inflation readings
Yesterday at 09:37 AM 30
Go to forecasts